Overview / Abstract: |
Targeted agents such as Bruton tyrosine kinase (BTK) inhibitors dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Unfortunately, challenges with tolerance and resistance are pervasive with these agents. Novel highly selective, non-covalent (reversible) BTK inhibitors that may overcome these challenges are undergoing investigation in clinical trials and have the potential to significantly enhance the treatment of CLL/SLL. In early clinical trials, these agents improved overall response rates, irrespective of prior therapy or mutation status. With the high volume of new clinical trial data related to CLL/SLL, the hematology/oncology team may be challenged to incorporate these new practice-altering therapies into current treatment plans. Ensure that your team is ready to introduce these therapies to best meet the needs of their diverse patients with CLL/SLL and engage with a leading oncology expert real-time. Schedule your virtual meeting today! |
Expiration |
Mar 31, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Grand Rounds, Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Chair Co-Chair Faculty Sameer Parikh, MD, MBBS |
Sponsors / Supporters / Grant Providers |
Sponsored by the Academy for Continued Healthcare Learning. |
Keywords / Search Terms |
ACHL grand rounds, virtual, Bruton’s tyrosine kinase, BTK inhibitors, chronic lymphocytic leukemia, CLL, small lymphocytic lymphoma, SLL, emerging therapies, hematology, oncology, precision medicine, targeted agents Free CE CME Seminar CE CME |
LIVE Activity Location Details |
Date(s)
Various |